Literature DB >> 17622775

Effect of addition of yohimbine (alpha-2-receptor antagonist) to the antidepressant activity of fluoxetine or venlafaxine in the mouse forced swim test.

Ashish Dhir1, S K Kulkarni.   

Abstract

BACKGROUND/AIMS: Studies have suggested that alpha(2)-adrenoceptors strongly affect monoaminergic neurotransmission by enhancing not only noradrenergic but also serotonergic firing rates. With this background in mind, the present study was undertaken to monitor the effect of addition of yohimbine (alpha(2)-adrenoceptor antagonist) to the effect of fluoxetine (selective serotonin reuptake inhibitor) or venlafaxine (dual reuptake inhibitors of both serotonin and norepinephrine) in Porsolt's forced swim test (FST) using male Laca strain mice.
METHOD: The immobility period was recorded in mouse FST during a 6-min period. Different doses of fluoxetine or venlafaxine were administered 30 min before exposing the animals to the test procedure. In the combination study, yohimbine (2 mg/kg i.p.) was administered 15 min before the administration of different doses of fluoxetine or venlafaxine.
RESULTS: Fluoxetine (5, 10, 20 and 40 mg/kg) [F = 28.352] or venlafaxine (2, 4, 8 and 16 mg/kg) [F = 17.842] dose-dependently inhibited the immobility period in mice. Addition of yohimbine (2 mg/kg i.p.) potentiated the antidepressant action of fluoxetine or venlafaxine in mouse FST as the animals showed a decrease in the immobility period compared to the fluoxetine or venlafaxine per se group, respectively.
CONCLUSION: The present study not only demonstrated the association of alpha(2)-receptors in the antidepressant effect of fluoxetine or venlafaxine, but also supports its adjuvant therapy with other antidepressant drugs. (c) 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17622775     DOI: 10.1159/000104877

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  8 in total

1.  Too Depressed to Swim or Too Afraid to Stop? A Reinterpretation of the Forced Swim Test as a Measure of Anxiety-Like Behavior.

Authors:  Jeffrey Anyan; Shimon Amir
Journal:  Neuropsychopharmacology       Date:  2017-10-31       Impact factor: 7.853

2.  Omega-3 fatty acid deficient male rats exhibit abnormal behavioral activation in the forced swim test following chronic fluoxetine treatment: association with altered 5-HT1A and alpha2A adrenergic receptor expression.

Authors:  Jessica A Able; Yanhong Liu; Ronald Jandacek; Therese Rider; Patrick Tso; Robert K McNamara
Journal:  J Psychiatr Res       Date:  2013-12-06       Impact factor: 4.791

3.  Acute administration of leptin produces anxiolytic-like effects: a comparison with fluoxetine.

Authors:  Jing Liu; Jacob C Garza; Jamaur Bronner; Chung Sub Kim; Wei Zhang; Xin-Yun Lu
Journal:  Psychopharmacology (Berl)       Date:  2009-10-13       Impact factor: 4.530

4.  Behavioral and neuronal biochemical possible effects in experimental induced chronic mild stress in male albino rats under the effect of oral barley administration in comparison to venlafaxine.

Authors:  Inas E Darwish; Hala M Maklad; Iman H Diab
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2013-05-27

5.  cGMP Signaling, Phosphodiesterases and Major Depressive Disorder.

Authors:  Gillian W Reierson; Shuyu Guo; Claudio Mastronardi; Julio Licinio; Ma-Li Wong
Journal:  Curr Neuropharmacol       Date:  2011-12       Impact factor: 7.363

6.  Adjunctive treatment with asenapine augments the escitalopram-induced effects on monoaminergic outflow and glutamatergic neurotransmission in the medial prefrontal cortex of the rat.

Authors:  Carl Björkholm; Olivia Frånberg; Anna Malmerfelt; Monica M Marcus; Åsa Konradsson-Geuken; Björn Schilström; Kent Jardemark; Torgny H Svensson
Journal:  Int J Neuropsychopharmacol       Date:  2014-10-31       Impact factor: 5.176

Review 7.  Adverse Psychiatric Effects Associated with Herbal Weight-Loss Products.

Authors:  F Saverio Bersani; Marialuce Coviello; Claudio Imperatori; Marta Francesconi; Christina M Hough; Giuseppe Valeriani; Gianfranco De Stefano; Flaminia Bolzan Mariotti Posocco; Rita Santacroce; Amedeo Minichino; Ornella Corazza
Journal:  Biomed Res Int       Date:  2015-09-17       Impact factor: 3.411

Review 8.  Therapeutic Potential of Selectively Targeting the α2C-Adrenoceptor in Cognition, Depression, and Schizophrenia-New Developments and Future Perspective.

Authors:  Madeleine Monique Uys; Mohammed Shahid; Brian Herbert Harvey
Journal:  Front Psychiatry       Date:  2017-08-14       Impact factor: 4.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.